Log in
NASDAQ:JNCE

Jounce Therapeutics Stock Forecast, Price & News

$7.27
+0.58 (+8.67 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$6.77
Now: $7.27
$7.40
50-Day Range
$6.62
MA: $8.25
$10.33
52-Week Range
$2.85
Now: $7.27
$11.72
Volume272,210 shs
Average Volume591,117 shs
Market Capitalization$289.72 million
P/E Ratio11.73
Dividend YieldN/A
Beta1.66
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment that is in the IND-enabling phase. The company's product candidate includes JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Read More
Jounce Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.04 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840
Employees130

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$147.87 million
Cash Flow$1.81 per share
Book Value$5.25 per share

Profitability

Net Income$56.82 million

Miscellaneous

Market Cap$289.72 million
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$7.27
+0.58 (+8.67 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive JNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions

How has Jounce Therapeutics' stock price been impacted by COVID-19?

Jounce Therapeutics' stock was trading at $4.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, JNCE shares have increased by 69.9% and is now trading at $7.27.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Jounce Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Jounce Therapeutics
.

What stocks does MarketBeat like better than Jounce Therapeutics?

Wall Street analysts have given Jounce Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Jounce Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Jounce Therapeutics' next earnings date?

Jounce Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Jounce Therapeutics
.

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics, Inc. (NASDAQ:JNCE) announced its quarterly earnings data on Friday, November, 6th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.36.
View Jounce Therapeutics' earnings history
.

What price target have analysts set for JNCE?

5 equities research analysts have issued twelve-month target prices for Jounce Therapeutics' shares. Their forecasts range from $9.00 to $15.00. On average, they anticipate Jounce Therapeutics' stock price to reach $12.00 in the next year. This suggests a possible upside of 65.1% from the stock's current price.
View analysts' price targets for Jounce Therapeutics
.

Are investors shorting Jounce Therapeutics?

Jounce Therapeutics saw a decline in short interest in the month of October. As of October 15th, there was short interest totaling 954,200 shares, a decline of 40.0% from the September 30th total of 1,590,000 shares. Based on an average daily volume of 1,210,000 shares, the days-to-cover ratio is presently 0.8 days. Approximately 5.8% of the shares of the company are short sold.
View Jounce Therapeutics' Short Interest
.

Who are some of Jounce Therapeutics' key competitors?

What other stocks do shareholders of Jounce Therapeutics own?

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the following people:
  • Dr. Richard Murray, Pres, CEO & Director (Age 61, Pay $845.1k)
  • Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 55, Pay $561.11k)
  • Dr. Elizabeth G. Trehu, Chief Medical Officer (Age 60, Pay $555.66k)
  • Dr. James P. Allison, Founder
  • Dr. Thomas F. Gajewski, Founder
  • Dr. Robert D. Schreiber, Founder
  • Dr. Drew M. Pardoll M.D., Ph.D., Founder
  • Dr. Padmanee Sharma, Founder
  • Dr. Louis M. Weiner, Founder (Age 68)
  • Ms. Kimberlee Cobleigh Drapkin CPA, CPA, CFO & Treasurer (Age 52)

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.55%), Acadian Asset Management LLC (2.51%), Candriam Luxembourg S.C.A. (1.04%), State Street Corp (0.98%), Charles Schwab Investment Management Inc. (0.78%) and AQR Capital Management LLC (0.51%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray and Rock Ventures Ii LP Third.
View institutional ownership trends for Jounce Therapeutics
.

Which major investors are selling Jounce Therapeutics stock?

JNCE stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Acadian Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., BlackRock Inc., AXA S.A., State Street Corp, JPMorgan Chase & Co., and Raymond James Financial Services Advisors Inc.. Company insiders that have sold Jounce Therapeutics company stock in the last year include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray, and Rock Ventures Ii LP Third.
View insider buying and selling activity for Jounce Therapeutics
.

Which major investors are buying Jounce Therapeutics stock?

JNCE stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Hussman Strategic Advisors Inc., Ziegler Capital Management LLC, Cubist Systematic Strategies LLC, First Trust Advisors LP, Arrowstreet Capital Limited Partnership, Dupont Capital Management Corp, and Raymond James & Associates.
View insider buying and selling activity for Jounce Therapeutics
.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $7.27.

How big of a company is Jounce Therapeutics?

Jounce Therapeutics has a market capitalization of $289.72 million and generates $147.87 million in revenue each year. The company earns $56.82 million in net income (profit) each year or $1.66 on an earnings per share basis. Jounce Therapeutics employs 130 workers across the globe.

What is Jounce Therapeutics' official website?

The official website for Jounce Therapeutics is www.jouncetx.com.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.